staurosporine has been researched along with Triple Negative Breast Neoplasms in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Connelly, M; Fatima, I; Gautam, LN; González, MA; Ling, T; Miranda-Carboni, G; Rivas, F; Tran, M; Wood, RK | 1 |
| Kim, HS; Kim, T; Kim, YS; Ko, H; Lee, J; Suh, YG | 1 |
| Jiang, Y; Ouyang, L; Sun, D; Wang, J; Yang, S; Yao, D; Yu, Y; Zhang, J; Zhao, Y; Zhou, Y; Zhu, L | 1 |
| Chen, ZS; Li, D; Qiu, Y; Wu, L; Xu, J; Xu, S; Yang, DH; Yao, H; Zhou, M | 1 |
| Chaikuad, A; Couñago, RM; da Silva Santiago, A; Dos Reis, CV; Gehringer, M; Gerstenecker, S; Hu, Z; Knapp, S; Kudolo, M; Laufer, S; M Serafim, RA; Massirer, KB; Mezzomo, P; Schwalm, MP; Takarada, JE; Zender, L | 1 |
| Baselga, J; Bennett, KL; Colinge, J; Ibrahim, Y; Kerzendorfer, C; Klepsch, F; Kubicek, S; Lechtermann, H; Leitner, E; Macho-Maschler, S; Mair, B; Muellner, MK; Müller, AC; Nijman, SM; Rix, U; Serra, V; Superti-Furga, G; Trefzer, C | 1 |
| Kamada, S; Kawai, M; Kikkawa, U; Nakashima, A | 1 |
| Aprelikova, O; Bennett, CN; Caplen, NJ; Chu, IM; Green, JE; Hollingshead, MG; Luger, D; Michalowski, AM; Mittereder, LR; Piwinica-Worms, H; Shou, J; Tomlinson, CC | 1 |
8 other study(ies) available for staurosporine and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.
Topics: Abietanes; Antineoplastic Agents, Phytogenic; Apoptosis; Biological Products; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Molecular Structure; Stereoisomerism; Structure-Activity Relationship; Triple Negative Breast Neoplasms | 2015 |
Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines.
Topics: Antineoplastic Agents; Breast; Cell Line, Tumor; Cell Survival; Female; Humans; Lactones; Phosphorylation; Signal Transduction; STAT3 Transcription Factor; Triple Negative Breast Neoplasms | 2017 |
Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti-metastasis activities in triple negative breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Pyrimidines; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2017 |
Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Female; Heterocyclic Compounds; Humans; Polycyclic Compounds; Quinazolines; Triple Negative Breast Neoplasms | 2021 |
Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; In Vitro Techniques; Male; Mass Spectrometry; Mice; Microsomes, Liver; Models, Molecular; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Triple Negative Breast Neoplasms | 2022 |
Targeting a cell state common to triple-negative breast cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Delivery Systems; Female; Gene Expression Profiling; Humans; Intracellular Signaling Peptides and Proteins; Mice; Molecular Docking Simulation; Molecular Targeted Therapy; Protein Interaction Domains and Motifs; Protein-Tyrosine Kinases; Proteomics; Sequence Analysis, RNA; Signal Transduction; STAT3 Transcription Factor; Staurosporine; Syk Kinase; Transforming Growth Factor beta; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family.
Topics: Animals; Apoptosis; Aurora Kinase A; Aurora Kinase B; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Protein Kinase Inhibitors; Staurosporine; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cluster Analysis; Deoxycytidine; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mice; Protein Kinase Inhibitors; Protein Kinases; Retinoblastoma Protein; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; RNA Interference; RNA, Small Interfering; Staurosporine; Triple Negative Breast Neoplasms; Tumor Burden; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2012 |